




Theranexus

LABORATOIRE EN 1^{ÈRE} LIGNE
CONTRE LES MALADIES
NEUROLOGIQUES



THERANEXUS ANNOUNCES A SUCCESSFUL CLINICAL PHARMACOKINETIC STUDY AS PART OF THE DEVELOPMENT OF ITS DRUG CANDIDATES THN201 AND THN101

Lyon, 21 March 2018 – THERANEXUS, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, today announces the results for a clinical pharmacokinetic study of the glial modulator, THN01, a component of its drug candidates THN201 and THN101. The objective of the study was to determine the dose to be administered to achieve the target plasma exposure and to be able to make progress in the manufacture of pharmaceutical batches for clinical research programmes on the two drug candidates.

“We are very pleased with the results of this pharmacokinetics study, which means we can go on with our clinical development plan this year for our drug candidates THN201 and THN101” explains Werner Rein, medical director at Theranexus.

With its unique breakthrough approach, Theranexus aims to meet the medical needs of patients in 4 indications¹ including Alzheimer’s disease (THN201) and neuropathic pain (THN101).

The drug candidate THN201 is designed to treat neurocognitive disorders associated with Alzheimer’s disease. It consists of a combination of donepezil, the first line treatment for this disease, and low dose mefloquine acting on the activity of the glial cells. This drug candidate continues its specific clinical development in 2018. The neurocognitive disorders in the form of memory loss, reasoning and orientation problems, affect 37 million patients in G20 countries. Prevalence increases as the population ages and it is one of the main causes of dependence of the elderly.

The drug candidate THN101 aims to improve treatment of neuropathic pain. In the same way, it consists of a combination of the first line treatment for this type of pain, amitriptyline, and mefloquine, again at a low dose. This drug candidate also continues its specific clinical development in 2018. Neuropathic pain is generally caused by damage to the nervous system. To date, 100 causes are listed (phantom limb pain, post-chemotherapy pain etc.) and they affect almost 70 million people in Europe, the United States and Japan alone.

¹ Narcolepsy, Parkinson’s disease, Alzheimer’s disease and neuropathic pain.

ABOUT THERANEXUS

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body’s response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.

The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

More information at: www.theranexus-bourse.com



Contacts

THERANEXUS

Thierry Lambert

Financial and Administrative Director

investisseurs@theranexus.fr

ACTUS finance & communication

Caroline Lesage / Théo Martin

Investor Relations

+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75

theranexus@actus.fr

FP2COM

Florence Portejoie

Media Relations

+ 33 (0)6 07 76 82 83

fportejoie@fp2com.fr